Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. (Q50665402)

17 March 2018

title

Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. (English)

1 reference

17 March 2018

obsessive-compulsive disorder

1 reference

1 reference

11

1 reference

17 March 2018

Humberto Nicolini

13

1 reference

17 March 2018

Dan J. Stein

15

1 reference

17 March 2018

Bernardo Dell'Osso

Bernardo Dell'Osso

4

0 references

Jose Manuel Menchon

Jose M Menchon

12

0 references

Joseph Zohar

16

Joseph Zohar

1 reference

17 March 2018

Eric Hollander

6

Eric Hollander

1 reference

17 March 2018

author name string

Michael Van Ameringen

1

1 reference

17 March 2018

William Simpson

2

1 reference

17 March 2018

Beth Patterson

3

1 reference

17 March 2018

Naomi Fineberg

5

1 reference

17 March 2018

Luchezar Hranov

7

1 reference

17 March 2018

Georgi Hranov

8

1 reference

17 March 2018

Christine Lochner

9

1 reference

17 March 2018

Oguz Karamustafalioglu

10

1 reference

17 March 2018

Stefano Pallanti

14

1 reference

17 March 2018

language of work or name

English

0 references

publication date

15 January 2014

1 reference

17 March 2018

Journal of Psychopharmacology

published in

1 reference

17 March 2018

volume

28

1 reference

17 March 2018

issue

6

1 reference

17 March 2018

page(s)

596-602

1 reference

17 March 2018

Pharmacological management of treatment-resistant obsessive-compulsive disorder

cites work

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Double-Blind, Placebo-Controlled Trial of Topiramate Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Quality of life and disability in patients with obsessive-compulsive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Community survey of bipolar disorder in Canada: lifetime prevalence and illness characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

A score for predicting response to pharmacotherapy in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Comparison of obsessive-compulsive disorder patients with and without comorbid putative obsessive-compulsive spectrum disorders using a structured clinical interview

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Impact of obsessive-compulsive disorder on quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Randomized, Placebo-Controlled Trial of Exposure and Ritual Prevention, Clomipramine, and Their Combination in the Treatment of Obsessive-Compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Quality of life in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Quality-of-life impairment in depressive and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Psychological treatment of obsessive-compulsive disorder: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

The Effects of Topiramate Adjunctive Treatment Added to Antidepressants in Patients with Resistant Obsessive-compulsive Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0269881113517955

21 January 2018

Identifiers

DOI

10.1177/0269881113517955

1 reference

17 March 2018

1 reference

17 March 2018